Ascletis ASC30 U.S. Phase IIa Obesity Study Reaches Full Enrollment
October 20, 2025 | 16:13
Once-monthly depot formulation targets adherence barriers; investigators will now examine whether small-molecule GLP-1 agonists can match peptide efficacy without cold-chain burden.
Mobile Version